Proactive Investors - Run By Investors For Investors

Genedrive partners with FIND to evaluate Hepatitis C diagnostic kit in Cameroon and Georgia

Under the agreement, FIND will lead evaluation studies between September 2018 and May 2019 to confirm the accuracy of Genedrive’s HCV kit across diverse genotypes
Hepatitis C
The studies will also evaluate the kit's usability in its intended markets

Genedrive PLC (LON:GDR) has partnered with the Foundation for Innovation of New Diagnostics (FIND) in a study agreement to evaluate its hepatitis C virus (HCV) identification kit.

The AIM-listed biotechnology firm said under the agreement, FIND would lead evaluation studies in Cameroon and Georgia between September 2018 and May 2019 to confirm the accuracy of Genedrive’s HCV kit across diverse genotypes, as well as its usability in the intended market of low-resource areas.

READ: Genedrive shares push higher as the rapid diagnostics specialist gears up for important year

The company added that FIND’s evaluations would feed into the organisation’s broader efforts as part of a multi-year, multi-country HCV project funded by Unitaid to support the development of simple HCV diagnostic tools for use at the point of care.

David Budd, Genedrive’s chief executive, said positive outcomes of the study would facilitate the company’s commercialisation activities in the relevant regions, while also “providing important clinical field data that others look to as they decide to implement [the Genedrive diagnostics platform] in their own specific settings."

View full GDR profile View Profile

Genedrive PLC Timeline

Related Articles

June 27 2018
Lancor Scientific is aiming to carry out an initial coin offering by issuing Medici, a new currency based on Ethereum to help Tumour Trace to fund further development
Scientists in a lab
January 31 2019
CEO Gary Phillips says Pharmaxis’ healthy cash balance gives it time to choose between in-house and partnering options.
Cancer cells
February 12 2019
The AIM-listed group is at the vanguard of advances in the emerging field of immuno-oncology and is working on two technologies that are showing early promise

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use